• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Join the Alliance

The International Alliance of ALS/MND Associations encourages all organizations involved in support of people living with ALS/MND or have an interest in ALS/MND to apply for membership.

The Alliance offers three types of membership: Full, Affiliate, and Honorary. Each has its own criteria, application requirements, and fees.

Membership Criteria, Application Requirements & Fees

Full Membership

To qualify for Full Membership, an organization must:

  • Serve people with ALS/MND or related disorders with a focus on patient care, advocacy and/or research;
  • Be chartered in their own country as a non-profit national or independent organization for at least 2 years;
  • Have a legal constitution or by-laws;
  • Be governed by a volunteer Board of Directors (however described), elected by and/or from the membership which includes people living with ALS/MND, carers, past carers, or people closely associated with the disease; and
  • Prepare an annual financial statement.

Applicants for Full Membership must submit the following documents in English:

  • Cover letter stating their reasons for wanting to become a member of the Alliance
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement of the organization
  • Written financial statement of previous year’s income
  • Copies of or weblinks to brochures and other materials (if not in English, then with some English translation)

The fee for Full Membership is either an amount equal to 0.2% of total annual income of the applicant organization or £100 (Pounds Sterling), whichever is greater. At the discretion of the Board of Trustees, fees can be waived or reduced for members that demonstrate need and make a request in writing.

Affiliate Membership

Affiliate Membership in the Alliance falls within four categories:

  1. Emerging Associations Affiliate: New ALS/MND Associations being established or recently chartered in own country as a non-profit organization (or status pending) by July 1st of the current membership year.
  2. Network Affiliate:
    1. Regional non-profit networks of researchers and clinicians collaborating on ALS/MND
    2. Regional non-profit patient networks providing resources and support to people living with ALS/MND
    3. Non-profit neurological alliances advocating for and supporting people with neurological conditions
  3. Education and Research Affiliate: Education or research institutes and centres dedicated to ALS/MND that operate within a non-profit entity such as a university.
  4. Fiscal Sponsorship/Hosting Arrangement Affiliate: Organizations focused on ALS/MND that are not independently chartered and operate under the legal or administrative framework of a sponsoring or host organization.

To qualify for Affiliate Membership, an organization must:

  • Serve people with ALS/MND or related disorders with a focus on patient care, advocacy and/or research;
  • Be formally established in their own country as a non-profit organization, operate within a non-profit entity, or function under the legal or administrative structure of a sponsoring/host organization;
  • Be governed directly or indirectly by a legal constitution or by-laws;
  • Be governed by a volunteer Board of Directors (however described), elected by and/or from the membership that includes people living with ALS/MND, carers, past carers, or people closely associated with the disease; and
  • Prepare an annual financial statement (where administratively relevant).

Applicants for Affiliate Membership must submit the following documents in English:

  • Cover letter stating their reasons for wanting to become a member of the Alliance
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement of the organization
  • Written financial statement of previous year’s income (only for Emerging Associations, if available, and Network Affiliates)
  • Copies of or weblinks to brochures and other materials (if not in English, then with some English translation)

The fee for Affiliate Membership is £100 (Pounds Sterling). At the discretion of the Board of Trustees, fees can be waived or reduced for members that demonstrate need and make a request in writing.

Honorary Membership

Honorary Membership is awarded at the discretion of the Alliance’s Board of Trustees to individuals who have made significant contributions to the Alliance’s mission of a world free of ALS/MND. This may include former Board Members, Patrons, Staff, or Award recipients.

 

For any questions or to apply for membership, please contact the CEO at alliance@als-mnd.org.

The Board reviews applications quarterly. You will be notified of the decision by email.

We encourage prospective members to attend the Alliance Meeting. Observer status will be granted.

Primary Sidebar

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Zelina Brito, Brazil

    Zelina Brito, Brazil

  • JP

    JP

  • Liam Dwyer, England

    Liam Dwyer, England

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • Mike Small, UK

    Mike Small, UK

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Anthony Lynch, Australia

    Anthony Lynch, Australia

  • Mary Thomas, Australia

    Mary Thomas, Australia

  • Conny van der Meijden, Netherlands

    Conny van der Meijden, Netherlands

  • Frank Taylor, USA

    Frank Taylor, USA

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Jeff Sutherland, Canada

    Jeff Sutherland, Canada
    jspic

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • Brian Parsons, Canada

    Brian Parsons, Canada

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Denis Blais, Canada

    Denis Blais, Canada

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Shaleen Latchman, Canada

    Shaleen Latchman, Canada

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Debbie Craghill, USA

    Debbie Craghill, USA

  • Fayette Underwood, USA

    Fayette Underwood, USA

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Lombana, Spain

    Lombana, Spain

  • Susan Anderson, USA

    Susan Anderson, USA

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Michael Lee, Australia

    Michael Lee, Australia

  • Ali Var, Turkey

    Ali Var, Turkey

  • Danny Reviers, Belgium

    Danny Reviers, Belgium
    DannyReviers

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Philip Brindle, England

    Philip Brindle, England

  • Angelique van der Lit-van Veldhuizen, Netherlands

    Angelique van der Lit-van Veldhuizen, Netherlands

  • Hanne Stenmose, Denmark

    Hanne Stenmose, Denmark

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • H. Todd Kelly, USA

    H. Todd Kelly, USA

  • João Marcos Andrietta, Brazil

    João Marcos Andrietta, Brazil

  • Mike Rannie, Canada

    Mike Rannie, Canada

  • David Hall, USA

    David Hall, USA

  • Aida Trzmiel de Guterman, Argentina

    Aida Trzmiel de Guterman, Argentina

  • Claudette Sturk, Canada

    Claudette Sturk, Canada
    Picture2

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login